GlassScriptPhysician profile
Krishna Kakani
NPI 1568456655
$2,251.62
in general payments reported to CMS, 2019-2025
25 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $360 · 2021: $481 · 2022: $190 · 2023: $268 · 2024: $234 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.39 |
| Education | $206.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $451.42 | 2019-2024 | |
| Astellas Pharma US INC | $284.49 | 2019-2025 | Veozah, Myrbetriq |
| Lupin INC. | $172.45 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $142.08 | 2019-2020 | |
| Hologic Sales and Service, LLC | $138.05 | 2019-2020 | |
| Myovant Sciences INC. | $126.14 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $110.53 | 2023-2025 | Gemtesa, Myfembree |
| Millicent US INC | $106.80 | 2024 | |
| Pfizer INC. | $84.60 | 2019-2021 | |
| Exeltis, USA INC. | $76.84 | 2020-2024 | Slynd |
| Therapeuticsmd, INC. | $74.66 | 2019-2022 | |
| Scynexis, INC. | $60.22 | 2022 | |
| Mayne Pharma Commercial LLC | $57.39 | 2021-2024 | |
| Roche Diagnostics Corporation | $56.61 | 2019-2020 | |
| Boston Scientific Corporation | $48.35 | 2025 | Advantage System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $41.21 | 2021 | |
| Mylan Pharmaceuticals INC. | $36.53 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $35.45 | 2023 | Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $34.21 | 2025 | |
| Gen-Probe, INC. | $29.54 | 2019 | |
| Shield Therapeutics INC | $24.51 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $17.45 | 2020 | |
| Minerva Surgical, INC | $16.41 | 2023 | |
| Avion Pharmaceuticals | $12.92 | 2019 | |
| Agile Therapeutics, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Kakani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.